MCQOPTIONS
Saved Bookmarks
MCQOPTIONS
This section includes 14 Mcqs, each offering curated multiple-choice questions to sharpen your Biotechnology knowledge and support exam preparation. Choose a topic below to get started.
| 1. |
In vitro determination of bioavailability by dissolution rate is not the best way to determine therapeutic efficacy. |
| A. | True |
| B. | False |
| Answer» C. | |
| 2. |
Therapeutic response is based on observing the clinical response to a drug formulation. |
| A. | True |
| B. | False |
| Answer» B. False | |
| 3. |
Which of the following is not measured in acute pharmacological response study? |
| A. | ECG |
| B. | EEG |
| C. | Pupil diameter |
| D. | Serum drug level |
| Answer» E. | |
| 4. |
Find out the correct option for the marked place in the given picture of the rate of excretion versus midpoint time of urine collection period curve. |
| A. | (dXu/dt)max |
| B. | (tu)max |
| C. | Xu |
| D. | Cmax |
| Answer» B. (tu)max | |
| 5. |
Which of the following will not be a parameter that should be examined for urinary excretion data? |
| A. | (dXu/dt)max |
| B. | (tu)max |
| C. | Xu |
| D. | Cmax |
| Answer» E. | |
| 6. |
The urinary excretion of the unchanged drug is directly proportional to the plasma concentration of a drug. |
| A. | True |
| B. | False |
| Answer» B. False | |
| 7. |
What is the equation for bioavailability? |
| A. | [AUC]std Dstd τtest / [AUC]test Dtest τstd |
| B. | [AUC]test Dtest τstd / [AUC]std Dstd τtest |
| C. | [AUC]test Dstd τtest / [AUC]std Dtest τstd |
| D. | 1 / [AUC]std Dtest τstd |
| Answer» D. 1 / [AUC]std Dtest τstd | |
| 8. |
Which of the following is not an important parameter of plasma level time studies? |
| A. | Cmax |
| B. | Tax |
| C. | The area under the plasma level-time curve |
| D. | Steady state level |
| Answer» E. | |
| 9. |
Which of the following is the pharmacodynamics method of studying bioavailability? |
| A. | Acute pharmacologic response |
| B. | Plasma-level time studies |
| C. | Urinary excretion studies |
| D. | Stool excretion studies |
| Answer» B. Plasma-level time studies | |
| 10. |
Multiple dose study is better since we can understand the peak, valley, drug blood levels, etc. |
| A. | True |
| B. | False |
| Answer» B. False | |
| 11. |
Single-dose bioavailability studies are simple and common. |
| A. | True |
| B. | False |
| Answer» B. False | |
| 12. |
Which of the following is not an objective of bioavailability studies? |
| A. | Primary stages of development of suitable dosage form for new drug |
| B. | Determination of the influence of excipients, patient-related factors, etc |
| C. | Development of new formulations of the existing drugs |
| D. | Control the quantity of the drug to be administered |
| Answer» E. | |
| 13. |
What is the equation of bioavailable fraction? |
| A. | 1/Bioavailable dose |
| B. | 1/Administered dose |
| C. | Bioavailable dose/Administered dose |
| D. | Administered dose/Bioavailable dose |
| Answer» D. Administered dose/Bioavailable dose | |
| 14. |
What is bioavailability? |
| A. | The time of absorption of the drug from its dosage form |
| B. | The rate of absorption of the unchanged drug from its dosage form |
| C. | The time of absorption of the unchanged drug from its dosage form |
| D. | The rate of absorption of the drug from its dosage form |
| Answer» C. The time of absorption of the unchanged drug from its dosage form | |